<DOC>
	<DOC>NCT01833754</DOC>
	<brief_summary>This is an open-label, single-dose, parallel-group study conducted in healthy subjects and subjects with stage 4 renal impairment (RI) or end stage renal disease (ESRD) requiring hemodialysis to evaluate the safety, tolerability, and immunogenicity profile of romosozumab. Subjects will enroll in parallel into 1 of three treatment groups to receive a single dose of romosozumab.</brief_summary>
	<brief_title>Study of Romosozumab (AMG 785) Administered to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>INCLUSION CRITERIA ALL SUBJECTS : Males or females ≥ 50 years of age Body weight ≥ 45 and ≤ 110 kg Willing to adhere to calcium and vitamin D supplementation requirements Females must be of nonreproductive potential INCLUSION CRITERIA SUBJECTS WITH RENAL IMPAIRMENT (GROUPS 1 AND 2): Group 1 Stage 4 RI (estimated glomerular filtration rate (eGFR) 1529 mL/min/1.73 m2) Group 2 End stage renal disease requiring hemodialysis INCLUSION CRITERIA HEALTHY SUBJECTS (GROUP 3): • Renal function defined as an estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m2 EXCLUSION CRITERIA ALL SUBJECTS: History of metabolic or bone disease (except for metabolic bone disease in renal impairment (RI) subjects) History of osteoporosis, vertebral fracture, or fragility fracture of the wrist, humerus, hip, or pelvis after age 50 Recent bone fracture Vitamin D insufficiency Hypocalcemia or hypercalcemia Hypomagnesemia Hypophosphatemia Untreated hyper or hypothyroidism Females with a positive pregnancy test Males with pregnant partners Females who are lactating/breastfeeding or plan to breastfeed on study and for 3 months after receiving the dose of study drug History of spinal stenosis History of facial nerve paralysis Positive for human immunodeficiency virus (HIV) antibodies Positive for hepatitis B surface antigen or detectable hepatitis C Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical, or breast ductal carcinoma in situ) within 5 years before screening History of solid organ or bone marrow transplants EXCLUSION CRITERIA HEALTHY SUBJECTS (GROUP 3) Current hyper or hypoparathyroidism</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Osteoporosis, Bone, Renal, Insufficiency, Kidney, Hemodialysis, Impairment</keyword>
</DOC>